Statements (54)
| Predicate | Object |
|---|---|
| gptkbp:instance_of |
gptkb:vaccine
|
| gptkbp:administered_by |
injection
|
| gptkbp:approves |
gptkb:1970
gptkb:U._S._Food_and_Drug_Administration |
| gptkbp:associated_with |
post-exposure prophylaxis when combined with antibiotics
|
| gptkbp:booster_required |
every 6 to 12 months
|
| gptkbp:clinical_trial |
conducted for safety and efficacy
|
| gptkbp:clinical_use |
pre-exposure prophylaxis
|
| gptkbp:community_health |
increases preparedness for biological threats
reduces incidence of anthrax |
| gptkbp:contains |
inactivated Bacillus anthracis spores
|
| gptkbp:contraindication |
severe allergic reaction to vaccine components
|
| gptkbp:developed_by |
gptkb:U._S._Army_Medical_Research_Institute_of_Infectious_Diseases
|
| gptkbp:dosage_form |
intramuscular injection
|
| gptkbp:historical_significance |
used during anthrax outbreaks
used in response to bioterrorism threats |
| https://www.w3.org/2000/01/rdf-schema#label |
Anthrax Vaccine Adsorbed
|
| gptkbp:indication |
gptkb:military_personnel
laboratory workers handling anthrax first responders in bioterrorism events veterinarians working with infected animals |
| gptkbp:informed_consent_required |
prior to administration
|
| gptkbp:is_recommended_for |
high-risk individuals
|
| gptkbp:is_vulnerable_to |
inactivated vaccine
requires trained healthcare provider 3 doses at 0, 7, and 21 or 28 days adverse events monitored post-vaccination exploring combination with other vaccines high in healthy adults investigating long-term immunity ongoing studies to enhance formulation variable in immunocompromised individuals |
| gptkbp:marketed_as |
trade name Bio Thrax
|
| gptkbp:part_of |
gptkb:nuclear_weapons
|
| gptkbp:produced_by |
gptkb:Emergent_Bio_Solutions
|
| gptkbp:provides_guidance_on |
included in vaccination programs for at-risk groups
recommended by CDC for certain populations |
| gptkbp:research_focus |
reducing side effects
improving vaccine efficacy developing alternative delivery methods |
| gptkbp:shelf_life |
up to 24 months
|
| gptkbp:side_effect |
fatigue
headache nausea muscle aches mild fever local reactions at injection site |
| gptkbp:storage |
refrigerated at 2-8° C
|
| gptkbp:suitable_for |
pregnant women unless necessary
individuals with compromised immune systems |
| gptkbp:targets |
gptkb:disease
|
| gptkbp:used_for |
prevention of anthrax
|
| gptkbp:bfsParent |
gptkb:Bio_Thrax
|
| gptkbp:bfsLayer |
6
|